Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Centrally confirmed Stage IV/M1 mTNBC
Newly obtained tumor biopsy from metastatic site
Central determination of programmed cell death ligand 1 (PD-L1) tumor status
Received either one or two prior systemic treatments for metastatic breast cancer and have documented disease progression on or after the most recent therapy
Previously treated with an anthracycline and/or taxane in the neoadjuvant/adjuvant or metastatic setting
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days prior to study start
Adequate organ function
You may not be if
Participation in another clinical trial within 4 weeks
Monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks
Chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks
Active autoimmune disease that required systemic treatment in the past 2 years
Diagnosed with immunodeficiency or receiving systemic steroid therapy or another form of immunosuppressive therapy within 7 days
Known additional malignancy that required treatment or progressed in last 5 years
Known active brain metastases and/or carcinomatous meningitis
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand-1 (anti-PD-L1), anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte associated protein 4 \[CTLA-4\], OX-40, CD137) or previously participated in any pembrolizumab (MK-3475) clinical studies
Clareo Health | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
